To appraise the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma multiforme.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 836

Email enquiries


Companies sponsors Northwest Biotherapeutics (DCVax-L)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Brain Tumour Charity
  International Brain Tumour Alliance (IBTA)
Professional groups Association of British Neurologists
  Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
05 March 2024 A meeting was held between NICE and the company in early-February regarding next steps for the appraisal of DCVax-L for treating glioblastoma, and more information will be available in due course. NICE will continue liaising with the company and monitoring timelines.
23 December 2022 NICE continues to liaise with the company regarding next steps for this technology appraisal and will provide updates in due course.
22 December 2022 In progress
19 September 2018 The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course.
14 June 2018 Invitation to participate
03 April 2018 - 01 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 August 2017 As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018
26 January 2017 - 23 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual